Regulators Investigate Ozempic's Potential Link to Suicidal Thoughts

Regulators are examining three reports of self-harm and suicidal thoughts among individuals taking Ozempic and Saxenda, both GLP-1 receptor agonists used for weight loss. The European Medicines Agency's Pharmacovigilance Risk Assessment Committee is leading the review, which will conclude by November 2023. It is unclear whether the reported incidents were due to an underlying mental health condition or a direct result of the medications. While suicide is not currently listed as a side effect of Ozempic, experts emphasize the importance of diligently reviewing any potential health concerns related to approved drugs. Novo Nordisk, the manufacturer of these drugs, stated that patient safety is a top priority and they continuously monitor data and real-world use. The FDA has not announced a review of GLP-1 receptor agonists but routinely evaluates approved drugs for safety.